Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cellectis SA (ALCLS) EUR0.05

Sell:€11.50 Buy:€12.05 Change: €0.06 (0.51%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.06 (0.51%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.06 (0.51%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Contact details

8, rue de la Croix Jarry
+33 (1) 81691600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€540.25 million
Shares in issue:
45.46 million
Euronext Paris

Key personnel

  • Andre Choulika
    Director, Chief Executive Officer and Co-Founder, Member of the Executive Board
  • David Sourdive
    Co-Founder, Executive Vice President, Strategic Initiatives, Member of the Executive Committee, Director
  • Eric Dutang
    Chief Financial Officer, Member of the Executive Committee
  • Kyung Nam-Wortman
    Chief Human Resource Officer, Executive Vice President, Member of the Executive Committee
  • Jon Voss
    Executive Vice President - Global Quality, Member of the Executive Committee
  • Leopold Bertea
    Senior Vice President - Technical Operations - Europe, Member of the Executive Committee
  • Steven Doares
    Senior Vice President of US Manufacturing, Member of the Executive Committee
  • Mark Frattini
    Senior Vice President - Clinical Sciences
  • Philippe Duchateau
    Chief Scientific Officer, Member of the Executive Committee
  • Stephan Reynier
    Chief Regulatory and Compliance Officer, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.